文献速递心力衰竭与心肌病

血浆cBIN1评分与射血分数保留心衰及心血管住院的关联

Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
PubMed 文献 · JAMA Cardiol · 2018-01-01

本研究在门诊心衰诊所连续纳入52例确诊HFpEF患者,并与年龄性别匹配的健康志愿者及有心衰危险因素但无HFpEF的对照比较。血浆cBIN1评分(CS)在HFpEF患者中显著升高,诊断区分能力优于NT-proBNP,且CS≥1.80与1年心血管住院风险增加相关。

要点

  • HFpEF患者血浆CS中位数1.85,显著高于健康对照(-0.03)和危险因素对照(-0.08)。
  • CS诊断HFpEF的AUC为0.98,优于NT-proBNP的0.93(P<.001)。
  • CS≥1.80的HFpEF患者1年心血管住院风险比为3.8(95%CI 1.3-11.2;P=.02)。

核心结论

  • 血浆CS作为横管功能障碍标志物,可能辅助HFpEF诊断并预测心血管住院,但需进一步验证。

研究设计与样本

  • 队列研究,连续纳入52例确诊HFpEF患者(左室射血分数≥50%),与年龄性别匹配的健康志愿者及有心衰危险因素但无HFpEF的对照比较。
  • CS由酶联免疫吸附法测定的血浆cBIN1浓度计算,基线特征及1年纵向临床信息来自电子病历。

主要发现

  • HFpEF患者CS中位数(IQR)为1.85(1.51-2.28),健康对照为-0.03(-0.48至0.41),危险因素对照为-0.08(-0.75至0.42),P<.001。
  • CS诊断HFpEF的AUC为0.98(95%CI 0.96-1.00),NT-proBNP的AUC为0.93(95%CI 0.88-0.99),P<.001(对照为健康志愿者)。
  • CS诊断HFpEF的AUC为0.98(95%CI 0.97-1.00),NT-proBNP的AUC为0.93(95%CI 0.88-0.99),P<.001(对照为危险因素人群)。
  • 调整年龄、性别、体重指数和NT-proBNP后,CS≥1.80的HFpEF患者1年心血管住院风险比为3.8(95%CI 1.3-11.2;P=.02)。

临床怎么用

  • 对于疑似HFpEF患者,血浆CS可能作为辅助诊断工具,其区分能力优于NT-proBNP。
  • CS≥1.80可能提示HFpEF患者1年心血管住院风险较高,需加强随访管理。

局限性

  • 样本量较小(52例HFpEF),为单中心研究,结论需在更大队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transverse tubule remodeling is a hallmark of heart failure. Cardiac bridging integrator 1 (cBIN1) is a circulating membrane scaffolding protein that is essential for transverse tubule health, and its plasma level declines with disease. OBJECTIVE: To determine if a cBIN1-derived score can serve as a diagnostic biomarker of heart failure with preserved ejection fraction (HFpEF). DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, the cBIN1 score (CS) was determined from enzyme-linked immunoabsorbent assay-measured plasma cBIN1 concentrations from study participants in an ambulatory heart failure clinic at Cedars-Sinai Medical Center. Consecutive patients with a confirmed diagnosis of heart failure with preserved ejection fraction (HFpEF; defined by a left ventricular ejection fraction ≥50%) were recruited from July 2014 to November 2015 and compared with age-matched and sex-matched healthy volunteers with no known cardiovascular diagnoses and participants with risk factors for heart failure but no known HFpEF. Baseline characteristics and 1-year longitudinal clinical information were obtained through electronic medical records. Data analysis occurred from November 2016 to November 2017. MAIN OUTCOMES AND MEASURES: The analysis examined the ability of the CS and N-terminal pro-B-type natriuretic peptide (NT-proBNP) results to differentiate among patients with HFpEF, healthy control participants, and control participants with risk factors for heart failure. We further explored the association of the CS with future cardiovascular hospitalizations. RESULTS: A total of 52 consecutive patients with a confirmed diagnosis of HFpEF were enrolled (mean [SD] age, 57 [15] years; 33 [63%] male). The CS values are significantly higher in the patients with HFpEF (median [interquartile range (IQR)], 1.85 [1.51-2.28]) than in the 2 control cohorts (healthy control participants: median [IQR], -0.03 [-0.48 to 0.41]; control participants with risk factors only: median [IQR], -0.08 [-0.75 to 0.42]; P < .001). For patients with HFpEF, the CS outperforms NT-proBNP when the comparator group was either healthy control participants (CS: area under curve [AUC], 0.98 [95% CI, 0.96-1.00]; NT-proBNP level: AUC, 0.93 [95% CI, 0.88-0.99]; P < .001) or those with risk factors (CS: AUC, 0.98 [95% CI, 0.97-1.00]; NT-proBNP: AUC, 0.93 [95% CI, 0.88-0.99]; P < .001). Kaplan-Meier analysis of 1-year cardiovascular hospitalizations adjusted for age, sex, body mass index, and NT-proBNP levels reveals that patients with HFpEF with CS greater than or equal to 1.80 have a hazard ratio of 3.8 (95% CI, 1.3-11.2; P = .02) for hospitalizations compared with those with scores less than 1.80. CONCLUSIONS AND RELEVANCE: If further validated, the plasma CS, a marker of transverse tubule dysfunction, may serve as a biomarker of cardiomyocyte remodeling that has the potential to aide in the diagnosis of HFpEF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Nikolova AP, Hitzeman TC, Baum R, et al. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. JAMA Cardiol. 2018. PMID: 30383171. doi:10.1001/jamacardio.2018.3539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。